Samira Shaikhly, serving as the Chief People Officer for Septerna, Inc. (NASDAQ:SEPN), has completed a transaction involving the sale of company equity. According to regulatory filings, Shaikhly disposed of 2,178 shares of Septerna common stock, realizing a total value of $76,622 from the sale. The transaction was reported on June 29, 2026.
The sale followed the immediate exercise of stock options to acquire an identical number of shares. Shaikhly acquired the 2,178 shares through option exercises priced at $6.81 per share, resulting in a total acquisition cost of $14,832. These shares were subsequently sold at a price of $35.18 per share. The execution of this sale was facilitated under a Rule 10b5-1 trading plan, which Shaikhly established on October 31, 2025. This pre-arranged mechanism allows for the scheduled trading of securities in compliance with insider trading regulations.
Following the completion of these transactions, Shaikhly’s direct holding of Septerna common stock stands at 793 shares. The stock options involved in this transaction were part of a specific grant structure. Under the terms of this grant, one-forty-eighth of the shares vest and become exercisable in substantially equal monthly installments. These vesting events occur on each monthly anniversary of October 28, 2024, contingent upon Shaikhly’s continuous service to the company on each respective date. The options carry an expiration date set for September 22, 2034.
This insider activity unfolds as Septerna’s stock has experienced substantial movement over the past year, surging 216%. As of the reporting date, the shares were trading at $33.49, contributing to a market capitalization of $1.5 billion for the company. Market analysis suggests the stock is positioned near its Fair Value estimate. Evaluations indicate the company is trading in line with fair value metrics, providing a baseline for investor assessment of the firm’s current valuation relative to its prospects.
Concurrent with the insider transaction, Septerna has advanced its clinical pipeline. The company has initiated dosing in a Phase 1 clinical trial for SEP-479, an oral small molecule drug candidate designed to treat hypoparathyroidism. This trial is scheduled to enroll up to 150 healthy adult volunteers. The primary objective of this study is to assess the safety and effectiveness of the drug candidate.
Analyst coverage for Septerna reflects optimism regarding these clinical developments. H.C. Wainwright has reiterated a Buy rating for the stock, maintaining a $40 price target. This rating follows the commencement of the SEP-479 trial. The firm cited the strong potential of Septerna’s pipeline as a key driver for its valuation outlook. Additionally, Raymond James raised its price target for Septerna to $53. The firm highlighted the ongoing Phase 1 trial for SEP-479, noting that data from this study is expected to emerge in late 2026 or early 2027.
Further clinical progress supports the positive analyst sentiment. H.C. Wainwright reiterated its Buy rating and $40 price target after Septerna reported positive Phase 1 trial results for SEP-631. This drug candidate is designed to address chronic spontaneous urticaria. The trial results indicated that the drug was well-tolerated and effective in suppressing skin wheal formation. These findings support the potential for a once-daily dosing regimen for the treatment. Septerna plans to initiate a Phase 2b trial of SEP-631 in the second half of 2026. These developments underscore the company’s ongoing efforts to advance its clinical trial assets and pipeline.